Hermansen, Johanne U.
Yin, Yanping
Urban, Aleksandra
Myklebust, Camilla V.
Karlsen, Linda
Melvold, Katrine
Tveita, Anders A.
Taskén, Kjetil
Munthe, Ludvig A. http://orcid.org/0000-0002-0344-3654
Tjønnfjord, Geir E. http://orcid.org/0000-0002-7757-4091
Skånland, Sigrid S. http://orcid.org/0000-0003-1630-356X
Funding for this research was provided by:
Norges Forskningsråd (322898)
Stiftelsen Kristian Gerhard Jebsen (19, 19, 19)
Article History
Received: 21 November 2022
Accepted: 3 April 2023
First Online: 13 April 2023
Competing interests
: G.E.T. has received advisory board honoraria from Alexion Pharmaceuticals and Janssen-Cilag, study support from Mundipharma, and lecture honoraria from Novartis, Janssen-Cilag, Alexion Pharmaceuticals, and Mundipharma outside of this work. S.S.S. has received honoraria from AbbVie and AstraZeneca, and research support from TG Therapeutics outside of this work. BeiGene provided the compounds zanubrutinib, BGB-10188, and BGB-11417. The other authors declare no competing financial interests.